Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Cedrol promotes hair growth better than baricitinib by regulating immune cells.

In this study, oral contraceptive use in women with PCOS increased the expression of certain inflammatory gene markers, which were positively associated with metabolic abnormalities.

In this study, hirsute women treated with cyproterone acetate and ethinyloestradiol experienced significant reductions in sebum secretion and hair growth after several months.

This review discusses the role of contraceptives in dermatology, particularly for acne treatment and managing patients on teratogens, but reports no new clinical results.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

This article reviews diagnostic criteria and treatment options for polycystic ovary syndrome, focusing on hormonal and metabolic management strategies, and presents no new clinical data.

This study concluded that intramuscular administration of medium-dose cyproterone acetate with oral ethinylestradiol is highly effective in managing hirsutism, showing better response rates than high-dose oral treatment.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study reviewed baricitinib's efficacy and safety for treating alopecia areata and found that more patients achieved significant hair regrowth with baricitinib compared to placebo in two phase III trials. Mild to moderate side effects were reported, with additional study suggested for long-term effects.

This study found that astilbin downregulates effector CD4+ T cell activities through the CYP1B1/ROS/PPARγ pathway, suggesting its potential use in treating inflammation.

Hormonal contraceptives and therapies regulate organ functions and treat various conditions.

This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

This study reported that both drospirenone and chlormadinone acetate oral contraceptives had similar beneficial effects on clinical, metabolic, and hormonal parameters in women with polycystic ovary syndrome over six months.

This retrospective cohort study found that both spironolactone and bicalutamide significantly improved Sinclair grade in women with female pattern hair loss over 24 months, but spironolactone, especially at doses above 100 mg/day, resulted in greater efficacy, required less monitoring, and maintained comparable safety.

This article discusses the management of long-term cardiovascular risks in women with polycystic ovary syndrome and suggests that lifestyle changes may be more effective than metformin in reducing the incidence of type 2 diabetes.

This review found very low certainty in evidence regarding whether statins, alone or in combination with metformin, improve menstrual regularity or other outcomes like hirsutism, acne severity, and testosterone levels, with adverse events showing no significant differences across groups.

This study found that Diane®, a combination of cyproterone acetate and ethinyl estradiol, is an effective contraceptive and treatment for acne and seborrhea, but less effective for pronounced hair growth.

This study found that microbial adenosine and biotin treatments derived from Staphylococcus epidermidis Cicaria culture may help inhibit hair loss by maintaining the hair's growth phase.

This paper discusses a structure-based analysis to find new BRD4 inhibitors, identifying finasteride and amentoflavone as promising candidates for BET inhibition.

This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.

This source reports that clinical trials found oral baricitinib significantly improved hair regrowth in patients with severe alopecia areata, with 38.8% achieving at least 80% scalp hair coverage after 36 weeks on a 4-mg dose, compared to 6.2% with placebo in trial 1.